Kodiak Sciences shares soared over 150% at the opening bell after its drugs successfully passed a key trial. The stock continued to rise, doubling in value as the new eye disease drug matched up with Eylea in a phase 3 trial. Additional reports indicated the stock rose 172% as Kodiak's drugs targeted Regeneron's Eylea. The company's stock price rose sharply toward $100 following strong phase 3 key trial data for wet AMD.
More Top Stories
Beckenham ODEON cinema to close
The ODEON cinema in Beckenham is set to close with plans for a church to take over the building. The ODEON's v...
Eight sailors attempt suicide on USS Abraham Lincoln
Eight sailors in the USS Abraham Lincoln strike group tried to take their own lives during an extended deploym...
Dante Moore suffers head injury in game against USC
Oregon quarterback Dante Moore was hurt in a game against USC. He suffered a head injury and was rushed to the...
Hurricane season shows unusual activity in Pacific and Atlantic
Hurricane season is showing unexpected trends with increased activity in the Pacific Ocean and relative quiet...
2026 NRL Grand Final Features Sydney Roosters and Newcastle Knights
The 2026 NRL Grand Final will see the Roosters face the Newcastle Knights. The match is set after the Knights...
Gibbs-White back in England lineup for Spain game
Morgan Gibbs White is back in the England team. Her name is on the list for the Spain match. She was called up...
Community Report · News Roundup · Daily Digest · Local Briefing · Local Briefing · News Roundup · News Roundup · Daily Digest · Local Briefing · Local Briefing · News Roundup · Daily Digest · Weekly Review · News Roundup · Daily Digest · Latest Update · Local Briefing · Local Briefing · Daily Digest · News Roundup · Weekly Review · News Roundup · Weekly Review · Weekly Review · Daily Digest · Weekly Review · Daily Digest · Latest Update · Local Briefing · News Roundup · Weekly Review · Community Report · Latest Update · Latest Update · Weekly Review · News Roundup · Weekly Review · Daily Digest · Local Briefing · Latest Update